Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 30, 1931-1936, July 1, 1970]
© 1970 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fugmann, R. A.
Right arrow Articles by Stolfi, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fugmann, R. A.
Right arrow Articles by Stolfi, R. L.

Enhanced Cures of Spontaneous Murine Mammary Carcinomas with Surgery and Five-Compound Combination Chemotherapy, and Their Immunotherapeutic Interrelationship1

Ruth A. Fugmann, Daniel S. Martin2, Peggy E. Hayworth and Robert L. Stolfi

Department of Surgery [D. S. M.] and Division of Surgical Immunology [R. A. F., P. E. H., R. L. S.], Catholic Medical Center, Jamaica, New York 11432

Therapeutic interrelationships among the modalities of surgery, combination chemotherapy, and immunotherapy have been documented for a spontaneous murine mammary adenocarcinoma.

The lifetime cure rates effected by surgical tumor enucleation plus the 4-compound combination, STEM (Streptonigrin, Thioguanine, Endoxan, and Mitomycin C) were significantly enhanced by the addition of a fifth chemical agent, actinomycin D (A), to the therapeutic regimen, i.e., surgery plus STEAM.

The combination chemotherapy was administered as a high-dosage, intermittent, short-term regimen to minimize host toxicity and avoid depression of the immune response of the host. Under these conditions, a further slight augmentation of lifetime cure rates was effected by administering zymosan as nonspecific immune stimulation along with the chemotherapeutic agents.

The participation of host immunity in attaining the high tumor cure rates was demonstrated by a marked reduction in cures when the immunosuppressant, cortisone, was administered concomitantly with the combination chemotherapy following surgery.

1 This research was supported by USPHS Grant CA-04497 and Grant RO 1 CA 11281-01 from the National Cancer Institute.

2 Address reprint requests to: Dr. Daniel S. Martin, Chairman, Department of Surgery, Catholic Medical Center, 88-25 153rd Street, Jamaica, N. Y. 11432.

Received 12/29/69. Accepted 3/11/70.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1970 by the American Association for Cancer Research.